Vaccination Programme Data

Dáil Éireann Debate, Tuesday - 26 June 2018

Tuesday, 26 June 2018

Ceisteanna (361)

Clare Daly

Ceist:

361. Deputy Clare Daly asked the Minister for Health the number of doses of the HPV vaccine administered here to date; and the number of cases of anaphylactic or anaphylactoid reactions reported to the Health Products regulatory Authority, HPRA, within the first three years of the vaccine being administered through the school system, that is between 1 September 2010 and 1 June 2013, before the number of vaccine doses per patient was reduced from three to two in 2014. [27638/18]

Freagraí scríofa

Minister for Health

As information concerning the number of doses of HPV vaccine administered is a service matter, it has been referred to the Health Service Executive for attention and direct reply to the Deputy. 

The information that the Deputy seeks concerning the number of cases of anaphylactic or anaphylactoid reactions is not readily available.  Therefore, I have asked the Health Products Regulatory Authority (HPRA) to investigate the matter and reply directly to the Deputy.

It is important to reiterate that the HPRA and the European Medicines Agency continually monitor adverse events to vaccination.  HPV is one of the most closely studied and monitored medicinal products.  The vast majority of reports received by the HPRA have been consistent with the expected pattern of short term adverse side effects for the vaccine, as described in the product information.  Mild and temporary reactions to any kind of vaccination are not unusual.